Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether aspirin resistance has impact on cardiovascular event in dialysis patient.
| Condition |
|---|
|
End Stage Renal Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Cross-Sectional |
| Official Title: | Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient |
- cardiovascular event, bleeding event,and thrombosis [ Time Frame: 1 year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 300 |
| Study Start Date: | December 2009 |
| Estimated Study Completion Date: | July 2010 |
| Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
aspirin responsive
PFA Col/EPI normal
|
|
aspirin resistance
PFA Col/epi showed resistance
|
Detailed Description:
Dialysis patient inevitably suffered from uremic bleeding although improvement of dialysis care in the past decades. Physicians used to check bleeding time as a surrogate marker for uremic bleeding. However, bleeding time isn't accurate and as well known, is poorly correlated with clinical bleeding such as surgical bleeding. Platelet function assay (PFA) is a newly developed method to measure platelet aggregation in vitro and is validated in many sorts of platelet disorders. Recently, PFA was also used to evaluate aspirin responsiveness in patients who had taken aspirin. Our study is aim to investigate uremic thrombocytopathy via PFA of dialysis patient in Taiwan. Furthermore, we will study aspirin resistance in dialysis patient.
Eligibility| Ages Eligible for Study: | 20 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Dialysis patients which follow-up at least monthly at National Taiwan University Hospital
Inclusion Criteria:
- dialysis >3 months
- Hb>10 g/dl & Plt > 10000
Exclusion Criteria:
- using medication which interfere PFA except aspirin
- terminal disease such as malignancy
- active vasculitis
Contacts and Locations| Taiwan | |
| National Taiwan University Hospital | |
| Taipei, Taiwan, 100 | |
| Principal Investigator: | Jenqwen Huang, MD | National Taiwan University Hospital |
More Information
Additional Information:
Publications:
| Responsible Party: | Jenqwen Huang, Internal Medicine, National Taiwan University Hospital |
| ClinicalTrials.gov Identifier: | NCT01045785 History of Changes |
| Other Study ID Numbers: | 200912018R |
| Study First Received: | January 8, 2010 |
| Last Updated: | January 8, 2010 |
| Health Authority: | Taiwan: Department of Health |
Keywords provided by National Taiwan University Hospital:
|
aspirin resistance, platelet function assay, dialysis, end stage renal disease |
Additional relevant MeSH terms:
|
Kidney Diseases Kidney Failure, Chronic Urologic Diseases Renal Insufficiency, Chronic Renal Insufficiency Aspirin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions |
Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents Hematologic Agents Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics Central Nervous System Agents |
ClinicalTrials.gov processed this record on June 18, 2013